the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity. *Nature Medicine 2:899-905.*

42. Ramierz, F., D. J. Fowell, M. Puklavec, S. Simmonds, and D. Mason. 1996. Glucocorticoids promote a TH2 cytokine response by CD4+ T cells in vitro. *J Immunol156:2406-12.*
43. Saoudi, A., S. Simmonds, I. Huitinga, and D. Mason. 1995. Prevention of experimental allergic encephalomyelitis in rats by targeting autoantigen to B cells: evidence that the protective mechanism depends on changes in the cytokine response and migratory properties of the autoantigen-specific T cells [see comments]. *J Exp Med 182:335-44.*
44. Thornhill, M. H., S. M. Wellicome, D. L. Mahiouz, J. S. Lanchbury, A. U. Kyan, and D. O. Haskard. 1991. Tumor necrosis factor combines with IL-4 or IFN-gamma to selectively enhance endothelial cell adhesiveness for T cells. The contribution of vascular cell adhesion molecule-1-dependent and -independent binding mechanisms. *J Immunol 146:592-8.*
45. Baron, J. L., J. A. Madri, N. H. Ruddle, G. Hashim, and C. J. Janeway. 1993. Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. *J Exp Med 177:57-68.*
46. Yednock, T. A., C. Cannon, L. C. Fritz, M. F. Sanchez, L. Steinman, and N. Karin. 1992. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. *Nature 356:63-6.*
47. Kuroda, Y., and Y. Shimamoto. 1991. Human tumor necrosis factor-alpha augments experimental allergic encephalomyelitis in rats. *J Neuroimmunol 34:159-64.*
48. Powell, M. B., D. Mitchell, J. Lederman, J. Buckmeier, S. S. Zamvil, M. Graham, N. H. Ruddle, and L. Steinman. 1990. Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein-specific T cell clones correlates with encephalitogenicity. *Int Immunol 2:539-44.*
49. Ruddle, N. H., C. M. Bergman, K. M. McGrath, E. G. Lingenheld, M. L. Grunnet, S. J. Padula, and R. B. Clark. 1990. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. *J Exp Med 172:1193-200.*
50. Selmaj, K., C. S. Raine, and A. H. Cross. 1991. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. *Ann Neurol 30:694-700.*

51. Kohno, K., J. Kataoka, T. Ohtsuki, Y. Suemoto, I. Okamoto, M. Usui, M. Ikeda, and M. Kurimoto. 1997. IFN-gamma-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. *J Immunol 158:1541-50.*

52. Rothe, H., N. A. Jenkins, N. G. Copeland, and H. Kolb. 1997. Active stage of autoimmune diabetes is associated with the expression of a novel cytokine, IGIF, which is located near Idd2. *J Clin Invest 99:469-74.*

53. Karin, N., J. D. Mitchell, S. Brocke, N. Ling, and L. Steinman. 1994. Reversal of experimental autoimmune encephalomyelitis by as soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of IFN-g and TNF-a production. *J. Exp. Med. 180:2227-2237.*

54. Grewal, I. S., H. G. Foellmer, K. D. Grewal, J. Xu, F. Hardardottir, J. L. Baron, C. A. Janeway, Jr., and R. A. Flavell. 1996. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. *Science 273:1864-7.*

55. Krakowski, M., and T. Owens. 1996. Interferon-gamma confers resistance to experimental allergic encephalomyelitis. *Eur J Immunol 26:1641-6.*

56. Heremans, H., C. Dillen, M. Groenen, E. Martens, and A. Billiau. 1996. Chronic relapsing experimental autoimmune encephalomyelitis (CREAE) in mice: enhancement by monoclonal antibodies against interferon-gamma. *Eur J Immunol 26:2393-8.*

57. Billiau, A., H. Heremans, F. Vandekerckhove, R. Dijkmans, H. Sobis, E. Meulepas, and H. Carton. 1988. Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-gamma. *J Immunol 140:1506-10.*

58. Segal, B. M., B. K. Dwyer, and E. M. Shevach. 1998. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. *J Exp Med 187:537-46.*

WHAT IS CLAIMED IS:

1. An antibody comprising an immunoglobulin capable of binding an interferon gamma inducing factor.

2. The antibody of claim 1, wherein the antibody is polyclonal.

3. The antibody of claim 1, wherein the antibody is monoclonal.

4. The antibody of claim 1, wherein said antibody is a neutralizing antibodies to said interferon gamma inducing factor in affecting cells to produce interferon gamma.

5. The antibody of claim 1, wherein the antibody is humanized.

6. A method for treating an animal for inducing protective immunity against multiple sclerosis, the method comprising the step of administering to said animal cells being capable of producing and secreting an antibody capable of neutralizing an interferon gamma inducing factor in affecting cells to produce interferon gamma.

7. The method of claim 6, wherein the antibody is humanized.

8. A method for treating an animal for inducing protective immunity against multiple sclerosis, the method comprising the step of administering to said animal an antibody capable of neutralizing an interferon gamma inducing factor in affecting cells to produce interferon gamma.

9. The method of claim 8, wherein the antibody is humanized.

10. A pharmaceutical composition for inducing protective immunity against multiple sclerosis, comprising a pharmaceutically acceptable carrier and an antibody being capable of binding an interferon gamma inducing factor.